Xencor Inc (NASDAQ:XNCR) insider John J. Kuch sold 25,000 shares of the business’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $41.64, for a total transaction of $1,041,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Xencor opened at $40.18 on Monday, according to Marketbeat Ratings. Xencor Inc has a 1 year low of $18.55 and a 1 year high of $43.39. The firm has a market cap of $2.24 billion, a PE ratio of -38.27 and a beta of 1.63.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.16). Xencor had a negative net margin of 137.35% and a negative return on equity of 18.07%. sell-side analysts expect that Xencor Inc will post -2.33 EPS for the current year.
Several brokerages have recently issued reports on XNCR. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a report on Friday, May 11th. Leerink Swann reissued an “outperform” rating and set a $36.00 price target on shares of Xencor in a report on Wednesday, March 28th. Canaccord Genuity boosted their price target on shares of Xencor from $36.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, May 9th. ValuEngine raised shares of Xencor from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $37.00 price target on shares of Xencor in a report on Thursday, March 29th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $37.88.
A number of hedge funds have recently bought and sold shares of XNCR. Redmile Group LLC lifted its holdings in Xencor by 137.2% in the first quarter. Redmile Group LLC now owns 3,204,343 shares of the biopharmaceutical company’s stock worth $96,066,000 after purchasing an additional 1,853,449 shares during the period. BVF Inc. IL acquired a new stake in Xencor in the first quarter worth about $27,042,000. PointState Capital LP acquired a new stake in Xencor in the first quarter worth about $14,300,000. Artal Group S.A. lifted its holdings in Xencor by 200.0% in the first quarter. Artal Group S.A. now owns 300,000 shares of the biopharmaceutical company’s stock worth $8,994,000 after purchasing an additional 200,000 shares during the period. Finally, Farallon Capital Management LLC acquired a new stake in Xencor in the first quarter worth about $4,494,000. 79.62% of the stock is owned by institutional investors and hedge funds.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.